Voss S D, Sondel P M, Robb R J
Department of Human Oncology, University of Wisconsin Clinical Sciences Center, Madison 53792.
J Exp Med. 1992 Aug 1;176(2):531-41. doi: 10.1084/jem.176.2.531.
Interleukin 2 (IL-2) receptors expressed on the surface of activated T cells and natural killer (NK) cells exhibit a variety of affinity states depending on their subunit composition. Low-affinity binding is associated with a 55-kDa alpha chain, intermediate-affinity binding with a 70-75-kD beta chain, and high-affinity binding with a bimolecular complex of the alpha and beta subunits. In a previous study of the IL-2 receptors expressed on NK cells obtained from cancer patients after in vivo IL-2 therapy, we documented a discrepancy between the level of beta chain and the level of intermediate-affinity IL-2 binding sites expressed on the cell surface. Based on this result, we postulated that formation of intermediate-affinity receptor sites required a component in addition to the beta chain, and that this component was present at limiting levels in the patient NK cells. In the present study we have examined the structure of the intermediate-affinity receptor complex using monoclonal antibodies that recognize the beta chain, but that do not interfere with its ability to bind IL-2. Evidence is presented establishing the physical association of a novel protein of 64 kD with the beta chain in intermediate-affinity IL-2 binding sites. This molecule, termed IL-2R gamma chain, coprecipitated with beta chains prepared from cells that had been incubated with IL-2, but was undetectable in immunoprecipitates prepared in the absence of IL-2. Examination of gamma chain expression in post-IL-2 therapy NK cells, where only low levels of intermediate-affinity IL-2 binding were detectable, revealed that the gamma chain was associated with, on average, only 10-12% of the beta chains expressed on such cells. This contrasted with approximately equal levels of beta and gamma chain expression on YT cells, a cell line that has both high levels of cell surface beta chain expression and high levels of IL-2 binding. Thus, the ratio of gamma chain to beta chain present in the immunoprecipitates roughly correlated with the proportion of beta chain involved in intermediate-affinity receptor sites. This result suggests that the 64-kD gamma chain is the component responsible for regulating the affinity of IL-2 association with the beta subunit. By further defining the structural components necessary for IL-2 receptor formation, these studies provide additional insight into mechanisms whereby lymphocytes might regulate their responsiveness to IL-2.
活化T细胞和自然杀伤(NK)细胞表面表达的白细胞介素2(IL-2)受体根据其亚基组成呈现出多种亲和力状态。低亲和力结合与55 kDa的α链相关,中等亲和力结合与70 - 75 kD的β链相关,高亲和力结合与α和β亚基的双分子复合物相关。在先前一项关于体内IL-2治疗后从癌症患者获取的NK细胞表面表达的IL-2受体的研究中,我们记录到细胞表面β链水平与中等亲和力IL-2结合位点水平之间存在差异。基于此结果,我们推测中等亲和力受体位点的形成除了β链外还需要一种成分,并且这种成分在患者NK细胞中含量有限。在本研究中,我们使用识别β链但不干扰其结合IL-2能力的单克隆抗体研究了中等亲和力受体复合物的结构。有证据表明一种64 kD的新蛋白与中等亲和力IL-2结合位点中的β链存在物理关联。该分子被称为IL-2Rγ链,与用IL-2孵育过的细胞制备的β链共沉淀,但在无IL-2条件下制备的免疫沉淀物中检测不到。对IL-2治疗后的NK细胞中γ链表达的检测发现,在此类细胞中仅能检测到低水平的中等亲和力IL-2结合,结果显示γ链平均仅与此类细胞上表达的约10 - 12%的β链相关。这与YT细胞上β链和γ链表达水平大致相等形成对比,YT细胞系具有高水平的细胞表面β链表达和高水平的IL-2结合。因此,免疫沉淀物中γ链与β链的比例大致与参与中等亲和力受体位点的β链比例相关。这一结果表明64 kD的γ链是负责调节IL-2与β亚基结合亲和力的成分。通过进一步明确IL-2受体形成所需的结构成分,这些研究为淋巴细胞调节其对IL-2反应性的机制提供了更多见解。